Royalty Receipts was $788 million in the first quarter of 2025, an increase of 12% compared to $705 million in the first quarter of 2024. The increase was primarily driven by strong growth from the ...

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of $169.00. Protect Your Portfolio ...

For female patients with multiple sclerosis (MS), transcutaneous posterior tibial nerve stimulation (TPTNS) and repetitive ...

In a new study led by scientists at the Wilmer Eye Institute, Johns Hopkins Medicine researchers say they have determined ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tom Yeung here with your Sunday Digest.  Last month, I wrote about ...

At this time, I'd like to welcome everyone to the Biogen first quarter 2025 earnings call and business update. (Operator Instructions). Today's conference is being recorded. Thank you. I would now ...

Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Biogen BIIB reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate ...

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

Biogen stock was muted Thursday after the biotech company beat Wall Street's first-quarter expectations, including strong sales for newcomer drugs Leqembi and Skyclarys.Leqembi, which partner Eisai ...